Glide takes 2 AI disease-prevention programmes from Abu Dhabi to New York

Abu Dhabi’s Global Institute for Disease Elimination (Glide) used UN General Assembly high-level week in New York to launch 2 AI health training programmes and extend the UAE’s prevention agenda beyond its home market, according to The National on 27 September 2026.

For UAE clinics, insurers and patients, the story is less about diplomacy than operating models. Dubai providers licensed by the Dubai Health Authority (DHA), Abu Dhabi providers overseen by the Department of Health Abu Dhabi (DOH), and northern emirates providers regulated by the Ministry of Health and Prevention (MOHAP) should treat prevention AI as a governance, data and reimbursement question before it becomes a procurement question.

What Glide announced in New York

Glide, based in Abu Dhabi, announced Glide Leadership Excellence in AI for Health for senior public health decision-makers and AI for All, a programme developed by Mohamed bin Zayed University of Artificial Intelligence and adapted with Glide for public health professionals. The institute also signed a Letter of Mutual Understanding with the RBM Partnership to End Malaria, with Nigeria co-hosting the event.

The National reported that Glide is working on about 14 projects across Africa, the Middle East and Latin America. One cited project in Madagascar uses AI-assisted microscopy to help detect multiple neglected tropical diseases in one diagnostic set-up. That matters to UAE operators because the same question will reach local chronic disease, cancer screening and preventive health programmes: can AI reduce avoidable specialist bottlenecks without weakening accountability?

“Progress towards malaria elimination depends on ensuring that global knowledge and innovation translate into practical capabilities at the country level,” said Dr Farida Al Hosani, chief executive of Glide.

Why UAE clinics and insurers should care

Dubai clinics should look first at referral pathways, consent language and data capture. Prevention AI depends on structured history, lab values, imaging reports and follow-up status. A clinic that cannot reliably capture those fields will struggle to prove value to payers such as Sukoon in Dubai or to Abu Dhabi payers and schemes such as Daman and Thiqa, where applicable.

COOs should not wait for a finished national rulebook before mapping the work. The operational checklist is short, but each item has cost and liability attached:

• Confirm which regulator applies: DHA for Dubai, DOH for Abu Dhabi and Al Ain, MOHAP for Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain.
• Ask vendors whether the AI tool is clinical decision support, diagnostics, patient engagement or population health analytics.
• Require written evidence for model validation, clinician oversight, data residency and adverse-event escalation.
• Track payer acceptance before launch, including pre-authorisation, direct billing and exclusion rules.

CFOs should price this as a compliance and integration project, not a software subscription alone. UAE regulators and insurers do not publish one standard tariff for AI-enabled prevention tools. Providers should obtain line-item quotations for system integration, health information exchange connection, model monitoring, staff training and annual legal review, then compare those costs with expected reductions in missed follow-ups, duplicated tests and late-stage referrals.

The UAE signal for prevention AI

Abu Dhabi has already put prevention and health data at the centre of its healthcare strategy. DOH supervises the emirate’s health system, while Abu Dhabi’s wider AI base includes MBZUAI and healthcare groups using genomics, chronic disease data and digital patient support. Glide’s New York work gives that model an external test: can UAE-built expertise work in countries with tighter budgets and fewer specialists?

Dubai operators should watch how this translates into private-sector expectations. If prevention AI gains credibility through public health programmes, insurers may ask clinics for earlier risk stratification, more complete disease registers and auditable follow-up processes. Patients may also compare clinics by whether they can identify risk before symptoms become expensive episodes of care.

The limitation is evidence. A New York announcement does not prove clinical or financial return inside a UAE outpatient setting. Medical directors should require local validation, named clinical owners and clear escalation rules before allowing AI outputs into diagnostic or treatment decisions. CIOs should insist that any tool can export usable records, support audit logs and fit existing privacy obligations.

For licensed provider options, patients and operators can use the UAE Open Healthcare Directory, which lists UAE healthcare providers anchored to DHA, DOH and MOHAP registers.